Barclays Capital Gives Equalweight Rating to Human Genome Sciences (HGSI)
Human Genome Sciences opened at 14.43 on Monday. Human Genome Sciences has a 1-year low of $6.51 and a 1-year high of $30.00. The company’s market cap is $2.873 billion.
HGSI has been the subject of a number of other recent research reports. Analysts at Leerink Swann downgraded shares of Human Genome Sciences from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, May 10th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Human Genome Sciences in a research note to investors on Friday, April 27th. They now have a $15.00 price target on the stock. Finally, analysts at JPMorgan Chase (NYSE: JPM) raised their price target on shares of Human Genome Sciences from $14.00 to $16.00 in a research note to investors on Wednesday, April 25th. They now have an “overweight” rating on the stock.
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company’s products are BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax.